

D/24 28/11

21st November 2014

The Corporation Finance Department,
Division of Corporate Restructuring
The Securities and Exchange Board of India
SEBI Bhavan,C4-A,
"G" Block,Bandra-Kurla Complex,
Bandra – (East),
Mumbai – 400 051

Dear Sir/Madam,

7,01

Please find enclosed our letter dated 21November 2014, requesting for an "Interpretative Letter" under the SEBI (Informal Guidance) Scheme, 2003 ("Scheme") regarding SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, in connection with the proposed acquisition of the shares of Elder Pharmaceuticals Limited ("Target Company").

Please find enclosed a demand draft for Rs. 25,000 (Rupees Twenty Five Thousand only) favouring 'Securities and Exchange Board of India' drawn on Kotak Mahindra Bank Ltd towards the fees payable in this respect under the Scheme.

If any information or clarification is required, please let us know.

Thanking you,

Yours faithfully,

For Apricot Capital Private Limited

Name: Dr. Anuj Saxena Designation: Director

Encl: As above

भा. प्र. वि. वो. SEDI सं / No <u>49 7/2</u> विनोक ate 28 NOV 2014



21st November' 2014

The Corporation Finance Department,
Division of Corporate Restructuring
The Securities and Exchange Board of India
SEBI Bhavan,C4-A,
"G" Block,Bandra-Kurla Complex,
Bandra – (East),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Request for "Interpretative Letter" under the SEBI (Informal Guidance) Scheme, 2003 regarding the implication of the proposed acquisition of the shares of Elder Pharmaceuticals Limited (Target Company) under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

This is to request for an Interpretative Letter under paragraph 5(ii) of the SEBI (Informal Guidance) Scheme, 2003 ("Scheme") regarding the exemption available for an *inter-se transfer* of shares in Elder Pharmaceuticals Limited between qualifying persons being promoters in terms of Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("Takeover Regulations").

A. BACKGROUND AND FACTS

1. Elder Pharmaceuticals Limited ("Target Company") is a company incorporated in India and having its registered office at Elder House, Plot No. C-9, Dalia Industrial Estate, Off Veera Desai Road, Andheri (West), Mumbai 400053. The Target Company is *inter alia*engaged in the business of manufacturing and marketing of pharmaceuticals and related products such as women's healthcare, wound care and pain management, neutraceuticals / vitamin supplements, life style and diabetes and antibiotics. In addition to the formulation business, the Target Company also offers medical equipments including oxygen concentrators and nebulisers and provides industrial equipment for instrumentation and weighing based automation applications.

2. The shares of the Target Company are presently listed on Bombay Stock Exchange Limited ("BSE") and National Stock Exchange of India limited ("NSE") (BSE and NSE are together referred as, the "Stock Exchanges").



- 3. The issued, subscribed and paid-up share capital of the Target Company is Rs. 20,53,69,360 consisting of2,05,36,936 equity shares of Rs. 10 each, of which 57,25,383 equity shares which represents 27.90% is held by the promoters and promoter group entities, as on 30 September 2014. The shareholding pattern of the Target Company as on 30 September 2014as filed with the stock exchanges in accordance with clause 35 of the Equity Listing Agreement is enclosed at **Annexure A.**
- 4. Apricot Capitals Private Limited("ACPL") is a private limited company incorporated in India and registered with the Registrar of Companies, Mumbai, Maharashtra bearing Company Identification Number (CIN)U65900MH2008PTC180275. The registered office of the Company is situated atElder House, Plot No. C-9, Dalia Industrial Estate, Off Veera Desai Road, Andheri (West), Mumbai 400053. The issued, subscribed and paid-up share capital of ACPL is Rs. 100,000 consisting of 10,000 equity shares of Rs. 10 each, of which 50% is held by Mr. Alok Saxena and 50% is held by Dr. Anuj Saxena. Mr. Alok Saxena and Dr. Anuj Saxena are brothers and members of the promoter group.
- 5. Semit Pharmaceuticals & Chemicals Limited ("Semit" or "First Transferor") is a public limited company incorporated in India and registered with the Registrar of Companies, Mumbai, Maharashtra bearing Company Identification Number (CIN)U24239MH1981PLC025454. The registered office of the Company is situated atManish Compound,Building No.1,2nd Floor,Gala No.3, Rahnal Village, Anjur Phata, Bhiwandi, Thane421302, Maharashtra. Semit holds 15,51,068equity shares of the Target Company which represents 7.55% of the paid-up share capital of the Target Company.
- 6. Indarts Exports Private Limited ("Indarts" or "Second Transferor") is a private limited company incorporated in India and registered with the Registrar of Companies, Mumbai, Maharashtra bearing Company Identification Number (CIN) U99999MH1984PTC034690. The registered office of the Company is situated at Motiram Patil Estate, Gala No.F-101, Cabin No.1, House No.654, Survey No.194, Purna Village, Bhiwandi, Thane 421302, Maharashtra. Indarts holds 15,80,995 equity shares of the Target Company which represents 7.70% of the paid-up share capital of the Target Company.
- 7. The promoters/promoter group of the Target Company includes Mr. Alok Saxena, Dr. Anuj Saxena (who are sons of late Mr. Jagdish Saxena), Semit, Indarts and other persons and entities. A list of the persons classified as promoters/promoter group in the Target Company's shareholding pattern as on 30 September 2014 as filed with the stock exchanges in accordance with clause 35 of the Equity Listing Agreement is enclosed at Annexure B.Mr. Alok Saxena, Dr. Anuj Saxena, Semit and Indarts have been holding shares in the Target Company for more than 3 (three) years.

The shareholding pattern of the Target Company as on 30 June 2011 as filed with the stock exchanges in accordance with clause 35 of the Equity Listing Agreement depicting Mr. Alok Saxena, Dr. Anuj Saxena, Semit, Indarts as promoters is enclosed at **Annexure C**.

8. Since Mr. Alok Saxena and Dr. Anuj Saxena, who are brothers (relatives) and promoters of the Target Company hold more than 10% of the equity share capital of ACPL, ACPL would form part of the promoter group of the Target Company and would be considered "promoter" in terms of Regulation 2(1)(s) of the Takeover Regulations.

Corp. Office: 3rd Floor, Bhukhanvala Chembers, B-28, Veera Industrial Estate, Off Link Andheri (W), Mumbai 400053, India. Tel +91 22 4092223 Fax: +91 22 40292233 E-mail: apricotcapitalspvtltd@apricotcapitals.com



B. TAKEOVER REGULATIONS (RELEVANT REGULATIONS)

Regulation 2(1)(zb) "promoter group" includes:

(i) the promoter; (ii); and

9. The definition of Promoter/Promoter Group has been given under the Takeover Regulations as under:

Regulation 2(1)(s)"promoter" has the same meaning as in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 and includes a member of the promoter group;

Regulation 2(1)(t)"promoter group" has the same meaning as in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;

The definition of the Promoter Group given under Regulation 2(1)(zb) of the Securities and Exchange Board of India (Issue of Capitaland Disclosure Requirements) Regulations, 2009, which states as under:

	(iv) in case the promoter is an individual:
	(A) any body corporate in which ten per cent or more of the equity share capital isheld by the promoter or an immediate relative of the promoter or a firm or Hindu Undivided Family in which the promoter or any one or more of hisimmediate relative is a member; (B); and (C); and
	(v) all persons whose shareholding is aggregated for the purpose of disclosing in the prospectus under the heading "shareholding of the promoter group":
	The expression "promoter" as defined under Regulation 2(1)(s) of the Takeover Regulations shall include a person belonging to the promoter group.
10.	Regulation 10(1)(a)(ii) of the Takeover Regulations provides an exemption for inter-se transfer of shares amongst "qualifying persons" as described below:
	Regulation 10. (1) The following acquisitions shall be exempt from the obligation to make anopen offer under regulation 3 and regulation 4 subject to fulfillment of the conditions stipulated therefor,— (a) acquisition pursuant to inter so transfer of phases amongst qualifying persons being
	(a) acquisition pursuant to inter se transfer of shares amongst qualifying persons, being,— (i);
	(ii) persons named as promoters in the shareholding pattern filed by the target company in terms of the listing agreement or these regulations for not less than three years prior to the proposed acquisition;
	(iv); (v);
	Provided that for purposes of availing of the exemption under this clause,—



(i) If the shares of the target company are frequently traded, the acquisition price per share shall not be higher by more than twenty-five per cent of the volume-weighted average market price for a period of sixty trading days preceding the date of issuance of notice for the proposed inter se transfer under sub-regulation (5), as traded on the stock exchange where the maximum volume of trading in the shares of the target company are recorded during such period, and if the shares of the target company are infrequently traded, the acquisition price shall not be higher by more than twenty-five percent of the price determined in terms of clause (e) of sub-regulation (2) of regulation 8; and (ii) the transferor and the transferee shall have complied with applicable disclosure requirements set out in Chapter V.

C. PROPOSED TRANSACTION AND APPLICABILITY OF TAKEOVER REGULATIONS

11. Pursuant to an internal arrangement agreed between the Promoters of the Target Company, it is proposed to transfer by way of gift, the equity shares of the Target Company held by "Acquirers") in the following manner:

No 1	Transferor	Transferees	Number of equity shares of Target Company to be transferred	% of the paid up capital of the Target Company
	Semit Pharmaceuticals & Chemicals Limited	Mr. Alok Saxena	100	0.0005
	And the second s	Dr. Anuj Saxena	100	0.0005
		Apricot Capitals Private Limited	15,50,868	7.55
2		Total - A	15,51,068	7.55%
	Indarts Exports Private Limited	Mr. Alok Saxena	100	0.0005
		Dr. Anuj Saxena	100	0.0005
		Apricot Capitals		0.0005
		Private Limited	15,80,795	7.70
-		Total - B	15,80,995	7.70%
		Total (A + B)	31,32,063	
				15.25%

- 12. We would like to further state as under:
 - a) Semit and Indarts, the Transferors, are qualifying persons, being promoters of the Target Company and have been holding equity shares in the Target Company for more than 3 \ (three) years and disclosed as promoters in the shareholding pattern filed by the Target Company in terms of clause 35 of the Equity Listing Agreement.
 - b) Mr. Alok Saxena and Dr. Anuj Saxena, being the Transferees, are qualifying persons, being promoters of the Target Company and have been holding equity shares in the Shareholding pattern filed by the Target Company in terms of clause 35 of the Extra Listing Agreement.



- c) ACPL, being one of the Transferees, does not hold any equity shares in the Target Company and has not held any equity shares in the Target Company for more than 3 (three) years, although it can be categorized as part of the promoter group in the Target Company as ACPL is 100% owned and controlled by Mr. Alok Saxena and Dr. Anuj Saxena who are promoters of the Target Company.
- 13. Since the proposed transfer to the Acquirers would be by way of gift, the provision of transfer price exceeding 25% of the volume-weighted average market price for a period of 60 sixty trading days preceding the date of issuance of notice for the proposed inter-se transferdoes not apply.
- 14. Pursuant to the above proposed transaction, there will be no change in the total promoter's shareholding in the Target Company and there will be no change in control of the Target Company.
- 15. We understand that inorder to claim exemption under Regulation 10(1)(a)(ii) of the Takeover Regulations for inter-se transfer of shares amongst "qualifying persons" as promoters, the condition of 3 (three) years shareholding by the transferors and the transferees prior to the proposed acquisition would be deemed to be fulfilled in case the transferors and transferees collectively hold shares for a period of 3 (three) years prior to the proposed acquisition subject to other conditions are fulfilled As in the present facts, since Mr. Alok Saxena and Dr. Anuj Saxena, being one of the transferees are holding shares for last 3 (three) years, it would be sufficient to qualify for exemption under Regulation 10(1)(a)(ii) of the Takeover Regulations even if other transferee, ACPL does not hold shares for 3 (three) years, prior to the transfer of shares.

D. REQUEST FOR INTERPRETATIVE LETTER

In view of the above facts, we seek an interpretation letter from SEBI on the following:

• Will the proposed transaction of transfer equity shares by gift from Semit and Indarts to ACPL and Mr. Alok Saxena and Dr. Anuj Saxena qualify for an exemption under Regulation 10(1)(a)(ii) of the Takeover Regulations, since Mr. Alok Saxena and Dr. Anuj Saxena, being one of the transferees in the proposed transaction, have held equity shares in the Target Company for more than 3 (three) years, even though ACPL does not hold any equity shares in the Target Company and such transaction will not be subject to an obligation to make an open offer to the shareholders of the Target Company under Regulation 3 and 4 of the Takeover Regulations.

Owing to the nature of the query, its likely impact on markets and the fact that no decision on sale/transfer has been taken by the relevant parties, we request that the subject matter and the contents of this letter be treated as confidential in accordance with paragraph 11 of the Scheme for the maximum period possible i.e. until 90 days after the response to this letter has been tendered.

All material facts, circumstances and legal previsions which in our opinion are relevant for purpose of determination of this request are stated hererin. We would appreciate receiving opinion on the issues contained in this letter at your earliest convenience.



In connection with our above application, we hereby authorizeDeloitte Touche Tohmatsu Private Limited, to co-ordinate, schedule meeting, do necessary follow up or liaise with SEBI office and also to provide necessary data, inputs, documents, clarifications, forward and receive emails with necessary attachments etc. on our behalf and details / submissions furnished by them in this connection would be binding on us. Their address is as under:

Deloitte Touche Tohmatsu Private Limited Indiabulls Finance Centre.

Tower 3, 28th Floor, Elphinstone Mill Compound,

Senapati Bapat Marg, Elphinstone (W), Mumbai – 400 013

Tel. Direct: +91 (22) 618541207

Fax: +91 (22) 6185 4101

Email: smaniar@deloitte.com or mmodi@deloitte.com

Kind Attn: Mr. Sameer Maniar / Mr. Mehul Modi

We would be happy to provide any further clarification or information that you may require.

For Apricot Capitals Private Limited

Name: Dr. Anuj Saxena
Designation: Director

Encl: As above

ELDER PHARMACEUTICALS LTD.

Scrip Code: 532322 Date Begin: 01 Jul 2014					Ending : Sept Date End : 3	
Partly paid-up shares	No. of partly paid-up share				al no. of share Sampany	s of the
Held by promoter/promoter group	, ,	0	0.00			0.00
held by public		0	0.00			0.00
Total		0	0.00			0.00
Outstanding convertible securities	No. of outstanding securities	As a % of total outstanding constanting security	nvertible	company assum	al no, of share ning full conve rtible securitie	rsion of the
Held by promoter/promoter group		0	0.00			0.00
held by public		0	0.00			0.00
Total		0	0.00			0.00
Warrants	No. of wagran	As a % of tot warran		company assu	al no, of share iming full con- warrants	
Held by promoter/promoter group		0	0.00			0.00
held by public		0	0.00			0.00
Total		0	0.00			0.00
Total Paid-up capital of the company assuming full conversion of warrants and convertible securities	20536					
Category of Shareholder No. of Shareholder	Total No. s of Shares	Total No. of Shares held in Dematerialize Form	ed a % of	nareholding as Total No. of Shares		ledged or encumbered
(A) Shareholding of Promoter and Promoter Group			As a % of (A+B)	As a % of (A+B+C)	Number of shares	As a % of Total No. of Shares
(1) Indian						
Individuals / Hindu Undivided Family	8 1081439	10814	139 5.2	7 5.27	494440	45.72
Bodies Corporate	10 4643944	46439	944 22.6	1 22.61	3955691	85.18
Sub Total	18 5725383	5725	383 27.8	8 27.88	4450131	77.73
(2) Foreign						
Total shareholding of Promoter and Promoter Group (A)	18 5725383	5725	383 27.8	8 27.88	4450131	77.73
(B) Public Shareholding						
(1) Institutions						
Mutual Funds / UTI	1 216	:	216 0.0	0.00	0	0.00
Financial Institutions / Banks	4 1873479	1873	479 9.1	2 9.12	0	0.00
Insurance Companies	1 380420	380	420 ` 1.8	5 1.85	0	0.00
Foreign Institutional Investors	4 3152739	3152	739 15.3	5 15.35	0	0.00
Sub Total	10 5406854	5406	854 26.3	3 26.33	0	0.00
(2) Non-Institutions						
• •				B	Timi	
Bodies Corporate 4	193 3258335	3257	982 15.8	7	Limited	0.00

http://www.bseindia.com/corporates/ShareholdingPattern.aspx?scripcd=53232

Individuals

Individual shareholders holding nominal share capital up to Rs. 1 lakh	25046	2893927	2727155	14.09	14.09	0	0.00
Individual shareholders holding nominal share capital in excess of Rs. 1 lakh	16	289781	274781	1.41	1.41	0	0.00
Any Others (Specify)	578	2962656	2918007	14.43	14.43	0	0.00
Foreign Corporate Bodies	1	2619000	2619000	12.75	12.75	0	0.00
Non Resident Indians	171	59096	59096	0.29	0.29	0	0.00
Trusts	2	1207	1207	0.01	0.01	0	0.00
Clearing Members	241	193126	193126	0.94	0.94	0	0.00
Directors & their Relatives & Friends	7	47364	38414	0.23	0.23	0	0.00
Office Bearer	81	33798	0	0.16	0.16	0	0.00
Hindu Undivided Families	24	1751	0	0.01	0.01	0	0.00
NRN	51	7314	7164	0.04	0.04	0	0.00
Sub Total	26133	9404699	9177925	45.79	45.79	0	0.00
Total Public shareholding (B)	26143	14811553	14584779	72.12	72.12	0	0.00
Total (A)+(B)	26161	20536936	20310162	100.00	100.00	4450131	21.67
(C) Shares held by Custodians and against which Depository Receipts have been issued	. 0	0	0	0.00	0.00	0	0.00
(1) Promoter and Promoter Group	0	0	0	0.00	0.00	0	0.00
(2) Public	0	0	0	0.00	0.00	0	0.00
Sub Total	0	0	0	0.00	0.00	0	0.00
Total (A)+(B)+(C)	26161	20536936	20310162	0.00	100.00	4450131	21.67

Notes:

- 1. For determining public shareholding for the purpose of Clause 40A 2. For definitions of Promoter and Promoter Group, refer to Clause 40A.
- 3. Public shareholding

Vijendra Jain

Company Secretary

Click here for Shareholding belonging to the category "Promoter and Promoter Group"

Click here for Shareholding belonging to the category "Public" and holding more than 1% of the Total No. of Shares

Click here for Shareholding belonging to the category "Public" and holding more than 5% of the Total No. of Shares

Click here for Details of Locked-in Shares

Click here for Details of Depository Receipts (DRs)

Click here for Holding of Depository Receipts (DRs), where underlying shares held by 'promoter/promoter group' are in excess of 1% of the total number of shares.

Click here for Details of Disclosure by Trading Members (TM) holding 1% or more of the Total No. of Shares.





ELDER PHARMACEUTICALS LTD

Scrip Code: 532322

Quarter ending: September 2014

Shareholding of securities (including shares, warrants, convertible securities) of persons belonging to the category Promoter and Promoter Group

SI.No.	Name of the Shareholder	Details of hel		Enc	Encumbered shares (*)			Details of warrants		convertible rities	Total shares (including underlying shares assuming full conversion of warrants and convertible securities) as a % of diluted share capital	
	,	No, of Sheres held	As a % of grand total (A)+ (B)+ (C)	No	As a percentage	As a % of grand total (A)+(B) +(C) of sub-dause (J)(a)	Number of warrants held	As a % total number of warrants of the same class	Number of convertible securities held	As a % total number of convertible securities of the same class		; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
1 🗸	Semit Pharmaceuticals & Chemicals Ltd	15,55,068	7.57	1552152	99.81	7.56	0	0.00	0	0.00	0.00	•
2 🔨	Industs Exports Vt Ltd	15,88,021	7.73	1532684	96.52	7.46	0	0.00	0	0.00	0.00	
3	Akshaya Holdings Pvt Ltd	6,92,370	3.37	562370	81.22	2.74	0	0.00	0	0.00	0.00	
4	Jagdish K Saxena	4,04,961	1.97	0	0.00	0.00	0	0.00	0	0.00	0.00	
5 🗸	Anuj J Saxena	2.60,450	1.27	260450	100.00	1.27	0	0.00	0	0.00	0.00	
6	Elder Health Care Limited	2.20,535	1.07	220535	100.00	1.07	0	0.00	0	0.00	0.00	j
7	Niti Saxena	2.15,150	1.05	215150	100.00	1.05	0	0.00	0	0.00	0.00	
8	Sneh J Saxena	1.28,210	0.62	0	0.00	0.00	0	0.00	0	0.00	0.00	• •
9	Elder Projects Limited	5,81,450	2.83	81450	14.01	0.40	0	0.00	. 0	0.00	0.00	3.5
10	Shalini Karan Raj Kumar	63,278	0.31	9450	14.93	0.05	0	0.00	0	0.00	0.00	à.
11	Alek Saxena	9,390	0.05	9390	100.00	0.05	0	0.00	0	0.00	0.00	
12	Elder Instruments Private Limited	6,500	0.03	6500	100.00	0.03	0	0.00	0	0.00	0.00	
	Total	57,25,383	27.88	4450131	77.73	21.67	0	0.00	0	0.00	0.00	Sia x

^(*) The term encumbrance has the same meaning as assigned to it in regulation 28(3) of the SAST Regulations, 2011.



ELDER PHARMACEUTICALS LTD.

Scrip Code : 532322					arter Ending Date End :		
Date Begin: 01 Apr 2011	No. of partly	As a % of total r	no, af	As a % of tota			
Partly paid-up shares	paid-up shares			. C	ompany		
Held by promoter/promoter group		0	0.00			0.00	
held by public		0	0.00			0.00	
Total		0	0.00			0.00	
Outstanding convertible securities	No. of outstanding securities	As a % of total outstanding conv securities	vertible (As a % of tota company assumi conver		rsion of the	•
Held by promoter/promoter group		0	0.00			0.00	•
held by public		0	0.00			0.00	
Total		0	0.00		,	0.00	
Warrants	No. of warrant	As a % of total warrants	no. of	As a % of tota company assu			
Held by promoter/promoter group		0	0.00			0.00	
held by public		0	0.00			0.00	À
Total		0	0.00			0.00	
Total Paid-up capital of the company assuming full conversion of warrants and convertible securities	205369	936					
No. of Category of Shareholder Shareholders	Total No. of Shares	Total No. of Shares held in Dematerialized Form	a % of	areholding as Total No. of Shares		oledged or encumbered	
(A) Shareholding of Promoter and Promoter Group		7	As a % of (A+B)	As a % of (A+B+C)	Number of shares	As a % of Total No. of Shares	
(1) Indian		ABATA 1000331 act	The second secon			ACCOUNTS OF THE PARTY OF THE PA	
Individuals / Hindu Undivided Family	8 1665111	161811	1 8.11	8.11	879000	52.79	
Bodies Corporate	9 6233988	623161	3 30.36	30.36	2754150	44.18	
Sub Total	17 7899099	784972	4 38.46	38.46	3633150	45.99	
(2) Foreign							
Total shareholding of Promoter and Promoter Group (A)	17 7899099	784972	4 38.46	38.46	3633150	45.99	
(B) Public Shareholding							
(1) Institutions							
Financial Institutions / Banks	7 552980	55298	30 2.69	2.69	0	0.00	
Insurance Companies	3 1315319	131531	9 6.40	6.40	0	0.00	· · · · · · · · · · · · · · · · · · ·
Foreign Institutional	27 4013199	401319	9 19.54	19.54	0	0.00	Ţ
							18.
Investors	37 5881498	588149	8 28.6	4 28.64	0	0.00	
Investors Sub Total	37 5881498	588149	98 28.64	4 28.64	0	0.00	
Investors Sub Total (2) Non-Institutions	37 5881498 253 1471683	588149 147133					

Individual shareholders holding nominal share capital up to Rs. 1 lakh	15583	1321830	1056939	6.44	6.44	0	0.00
Individual shareholders holding nominal share capital in excess of Rs. 1 lakh	8	181185	91185	0.88	0.88	0	0.00
Any Others (Specify)	217	3781641	3766641	18.41	18.41	0	0.00
Foreign Corporate Bodies	1	15000	0	0.07	0.07	0	0.00
Non Resident Indians	127	16807	16807	0.08	0.08	0	0.00
Trusts	2	1108778	1108778	5.40	5.40	0	0.00
Clearing Members	86	22056	22056	0.11	0.11	0	0.00
Foreign Nationals	1	2619000	2619000	12.75	12.75	0	0.00
1 oreign readonals							
Sub Total	16061	6756339	6386095	32.90	32.90	0	0.00
•			6386095 12267593	32.90 61.54	32.90 61.54	0	0.00
Sub Total	16061	6756339					
Sub Total Total Public shareholding (B)	16061 16098	6756339 12637837	12267593	61.54	61.54	0	0.00
Sub Total Total Public shareholding (B) Total (A)+(B) (C) Shares held by Custodians and against which Depository	16061 16098 16115	6756339 12637837 20536936	12267593 20117317	61.54 100.00	61.54 100.00	0 3633150	0.00 17.69
Sub Total Total Public shareholding (B) Total (A)+(B) (C) Shares held by Custodians and against which Depository Receipts have been issued (1) Promoter and Promoter	16061 16098 16115	6756339 12637837 20536936 0	12267593 20117317 0	61.54 100.00 0.00	61.54 100.00 0.00	0 3633150 0	0.00 17.69 0.00
Sub Total Total Public shareholding (B) Total (A)+(B) (C) Shares held by Custodians and against which Depository Receipts have been issued (1) Promoter and Promoter Group	16061 16098 16115 0	6756339 12637837 20536936 0	12267593 20117317 0 0	61.54 100.00 0.00 0.00	61.54 100.00 0.00 0.00	0 3633150 0 0	0.00 17.69 0.00

For determining public shareholding for the purpose of Clause 40A
 For definitions of Promoter and Promoter Group, refer to Clause 40A.

3. Public shareholding

S P Date Company Secretary

Click here for Shareholding belonging to the category "Promoter and Promoter Group"


Click here for Shareholding belonging to the category "Public" and holding more than 1% of the Total No. of Shares

Click here for Shareholding belonging to the category "Public" and holding more than 5% of the Total No. of Shares

Click here for Details of Locked-in Shares

Click here for Details of Depository Receipts (DRs)

Click here for Holding of Depository Receipts (DRs), where underlying shares held by 'promoter/promoter group' are in excess of 1% of the total number of shares.





ELDER PHARMACEUTICALS LTD

Scrip Code: 532322

Quarter ending: June 2011

Total shares (including

Shareholding of securities (including shares, warrants, convertible securities) of persons belonging to the category Promoter and Promoter Group

SI.No.	Name of the Shareholder	Details of held		Encumbered shares (*)			Delails of warrants		Details of convertible securities		underlying shares assuming full conversion of warrants and convertible securities) as a % of diluted share capital	
	Strateriologi	No. of Shares held	As a % of grand total (A)+ (B)+	No	As a percentage	As a % of grand lotal (A)+(B) +(C) of sub- clause (I)(a)	Number of warrants held	As a % total number of warrants of the same class	Number of convertible securities held	As a % total number of convertible securities of the same class		
1	Indarts Exports Pvt Ltd	75	0.00	0	0.00	0.00						
2	Semit Pharmaceuticals & Chemicals Pvt Ltd	2,300	0.01	0	0.00	0.00						
3	Indarts Exports Pvt Ltd	23,81,420	11.60	1621150	68.07	7.89						
4 .	Semit Pharmaceuticals & Chemicals Pvt Ltd	19,31,623	9.41	293000	15.17	1.43						
5	Akshaya Holdings Pvt Ltd	7,63,200	3.72	260000	34.07	1.27						
6	Elder Projects Ltd	5,81.450	2.83	580000	99.75	2.82						
7	Elder Health Care Ltd	2,99,535	1.46	0	0.00	0.00					No. il constitute and all constitutes.	
8	Elder Instruments Pvt Ltd	6,500	0.03	0	0.00	0.00						
9	Semi Pharmaceuticals & Chemicals Pvt Ltd	2,67,885	1.30	0	0.00	0.00						
10	Shalini Kumar	23,500	0.11	0	0.00	0.00						
11	Alok Jagdish Saxena	23,500	0.11	0	0.00	0.00						
12	Jagdish K Saxena	4,03.961	1.97	200000	49.51	0.97						
13	Sneh J Saxena	3,78,210	1.84	300000	79.32	1.46						
14	Shalini J Saxena	1,24,450	0.61	120000	96.42	0.58						
15	Niti Saxena	2,15.150	1.05	0	0.00	0.00						
16	Alok Saxena	2,35.890	1.15	0	0.00	0.00						
17	Dr. Anuj Saxena	2,60.450	1.27	259000	99.44	1.26						
	Total	78,99,099	38.46	3633150	45.99	17.69						

^(*) The term encumbrance has the same meaning as assigned to it in regulation 28(3) of the SAST Regulations, 2011.

